NCT00150241 - A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation | Biotech Hunter

Enrollment

625

Participants

Timeline

Start Date

February 29, 2000

Study Completion Date

January 31, 2002

Conditions

Smoking Cessation

Interventions

DRUG

CP-526,555 (varenicline)

Trial Locations (7)

Pfizer Investigational Site, Los Angeles

Pfizer Investigational Site, Farmington

Pfizer Investigational Site, Minneapolis

Pfizer Investigational Site, Omaha

Pfizer Investigational Site, New York

Pfizer Investigational Site, Portland

Pfizer Investigational Site, Morgantown